150 related articles for article (PubMed ID: 35592740)
1. CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways.
Al Shahrani M; Rajagopalan P; Abohassan M; Alshahrani M; Alraey Y
Saudi J Biol Sci; 2022 Jun; 29(6):103285. PubMed ID: 35592740
[TBL] [Abstract][Full Text] [Related]
2. High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma.
Al Shahrani M; Abohassan M; Y Alshahrani M; Hakami AR; Rajagopalan P
J Comput Aided Mol Des; 2021 Dec; 35(12):1165-1176. PubMed ID: 34727304
[TBL] [Abstract][Full Text] [Related]
3. Computational high-throughput screening and
Tobeigei FH; Gahtani RM; Shaikh A; Al Ali A; Kameli N; Kamli H; Rajagopalan P
Oncol Res; 2021; 29(5):305-318. PubMed ID: 37305163
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
5. Oxyfadichalcone C inhibits melanoma A375 cell proliferation and metastasis via suppressing PI3K/Akt and MAPK/ERK pathways.
Peng X; Wang Z; Liu Y; Peng X; Liu Y; Zhu S; Zhang Z; Qiu Y; Jin M; Wang R; Zhang Q; Kong D
Life Sci; 2018 Aug; 206():35-44. PubMed ID: 29782872
[TBL] [Abstract][Full Text] [Related]
6. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
[TBL] [Abstract][Full Text] [Related]
7. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
8. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.
Wang J; Chen J; Miller DD; Li W
Mol Cancer Ther; 2014 Jan; 13(1):16-26. PubMed ID: 24249714
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
11. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
12. Evodiamine inhibits growth of vemurafenib drug-resistant melanoma via suppressing IRS4/PI3K/AKT signaling pathway.
Guo X; Huang S; Zhang Y; Wang H; Li L; Ran J; Chen D; Li X; Li J
J Nat Med; 2024 Mar; 78(2):342-354. PubMed ID: 38324123
[TBL] [Abstract][Full Text] [Related]
13. Curcumin suppresses cell proliferation and triggers apoptosis in vemurafenib-resistant melanoma cells by downregulating the EGFR signaling pathway.
Chiu YJ; Yang JS; Tsai FJ; Chiu HY; Juan YN; Lo YH; Chiang JH
Environ Toxicol; 2022 Apr; 37(4):868-879. PubMed ID: 34994998
[TBL] [Abstract][Full Text] [Related]
14. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
15. Anticancer efficacy of 3-(4-isopropyl) benzylidene-8-ethoxy, 6-methyl, chroman-4-one (SBL-060), a novel, dual, estrogen receptor-Akt kinase inhibitor in acute myeloid leukemia cells.
Shahrani MA; Rajagopalan P; Abohassan M; Alshahrani M; Alraey Y; Gahtani RM; Radhakrishnan S; Dagreery K
Oncol Res; 2021; 29(3):149-157. PubMed ID: 37304671
[TBL] [Abstract][Full Text] [Related]
16. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
[TBL] [Abstract][Full Text] [Related]
18. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
[TBL] [Abstract][Full Text] [Related]
19. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
20. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]